人类免疫缺陷病毒 (HIV) 相关霍奇金淋巴瘤 (HIV-HL) 阶段适应治疗的前瞻性研究结果显示，2 年总生存率 (OS) 为 90.7%，早期有利 (EF)、早期不利（EU），晚期HL。 EF HIV-HL 患者接受 2 至 4 个周期的多柔比星、博莱霉素、长春碱和达卡巴嗪 (ABVD)  30 Gy 受累场 (IF) 放射治疗，EU HIV-HL 患者接受 4 个周期的 ABVD 或 BEACOPP（博莱霉素、依托泊苷、在晚期疾病中，给予阿霉素、环磷酰胺、长春新碱、丙卡巴肼和泼尼松）基线  30 Gy IF，以及六至八个周期的 BEACOPP 基线。本分析的目的是确定 HIV-HL 的长期结果。在 108 名患者中，23 名 (21%) 患有 EF HL，14 名 (13%) 患有 EU HL，71 名 (66%) 患有晚期 HL。中位随访时间为 9.14 年（范围为 0-12.9）后，有 5 名原发难治性 HL 患者（5%）和 11 名复发患者（10%），其中 7 名为晚期复发（>2 年）。 HL 诊断中位时间为 7.3 年（范围为 1.5-10.7 年）后，10 名患者出现第二原发性恶性肿瘤 (SPM)。 EF、EU 和晚期 HL 患者的 10 年 OS 分别为 95.7%、84.6% 和 76.1%。通过多变量分析，疾病控制和预防中心 C 类（风险比 [HR] 3.00，95% 置信区间 [CI]：1.16-7.74，p = 0.023）和完全缓解的实现对 OS 具有显着意义（HR 0.03，95） ％CI：0.01-0.08，p = 2.45 × 10-9）。总之，针对 HIV-HL 的阶段性治疗方法非常有效，其长期生存率与未感染 HIV 的 HL 相似。然而，晚期复发和 SPM 的风险很大。© 2024 作者。约翰·威利 (John Wiley) 出版的 HemaSphere

Results of a prospective study of stage-adapted treatment of human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HIV-HL) showed a 2-year overall survival (OS) of 90.7% with no significant difference between early favorable (EF), early unfavorable (EU), and advanced HL. Patients with EF HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation, those with EU HIV-HL received four cycles of ABVD or BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) baseline + 30 Gy IF, and six to eight cycles of BEACOPP baseline were administered in advanced disease. The objective of the present analysis is to determine long-term outcomes of HIV-HL. Of 108 patients, 23 (21%) had EF HL, 14 (13%) had EU HL, and 71 (66%) had advanced-stage HL. After a median follow-up of 9.14 (range, 0-12.9) years, there were five primary refractory HL patients (5%) and 11 relapses (10%), of which seven were late relapses (>2 years). A second primary malignancy (SPM) occurred in 10 patients after a median of 7.3 years (range, 1.5-10.7) from HL diagnosis. The 10-year OS for patients with EF, EU, and advanced HL was 95.7%, 84.6%, and 76.1%, respectively. By multivariate analysis, Center for Disease Control and Prevention category C (hazard ratio [HR] 3.00, 95% confidence interval [CI]: 1.16-7.74, p = 0.023) and achievement of complete remission were significant for OS (HR 0.03, 95% CI: 0.01-0.08, p = 2.45 × 10-9). In conclusion, a stage-adapted treatment approach for HIV-HL is highly effective with long-term survival rates similar to those reported in HIV-uninfected HL. However, the risk for late relapse and SPM is significant.© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.